PLoS ONE · 2012 · 14 citations · 32 references
MedicineCancer BiologyOncologyApoptosisCancer PharmacologyMolecular OncologyApoptosis ResistanceChemotherapy ResistanceGlutathione MetabolismMultiple MyelomaAnti-apoptotic RegulatorsApoptosis RegulatorsApoptotic Resistance MechanismsArsenic Resistance MechanismsGlutathione HomeostasisRefractory Multiple MyelomaRelapsed Multiple MyelomaResistance Pathways
Arsenic trioxide (ATO) has been tested in relapsed/refractory multiple myeloma with limited success. In order to better understand drug mechanism and resistance pathways in myeloma we generated an ATO-resistant cell line, 8226/S-ATOR05, with an IC50 that is 2-3-fold higher than control cell lines and significantly higher than clinically achievable concentrations. Interestingly we found two parallel pathways governing resistance to ATO in 8226/S-ATOR05, and the relevance of these pathways appears to be linked to the concentration of ATO used. We found changes in the expression of Bcl-2 family proteins Bfl-1 and Noxa as well as an increase in cellular glutathione (GSH) levels. At low, clinically achievable concentrations, resistance was primarily associated with an increase in expression of the anti-apoptotic protein Bfl-1 and a decrease in expression of the pro-apoptotic protein Noxa. However, as the concentration of ATO increased, elevated levels of intracellular GSH in 8226/S-ATOR05 became the primary mechanism of ATO resistance. Removal of arsenic selection resulted in a loss of the resistance phenotype, with cells becoming sensitive to high concentrations of ATO within 7 days following drug removal, indicating changes associated with high level resistance (elevated GSH) are dependent upon the presence of arsenic. Conversely, not until 50 days without arsenic did cells once again become sensitive to clinically relevant doses of ATO, coinciding with a decrease in the expression of Bfl-1. In addition we found cross-resistance to melphalan and doxorubicin in 8226/S-ATOR05, suggesting ATO-resistance pathways may also be involved in resistance to other chemotherapeutic agents used in the treatment of multiple myeloma.
32
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Lawrence Boise, Andy J. Minn, Patricia J. Noel et al. · Immunity · 1995 · 1.2K citations · Full text
Mechanisms of action of arsenic trioxide.
Wilson H. Miller, Hyman M. Schipper, Janet Lee et al. · PubMed · 2002 · 956 citations
Medicine, Hematology, Oncology +17
Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PML
Xiaowei Zhang, Zi‐Ren Zhou, Feifei Yang et al. · Science · 2010 · 775 citations
Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1
Derek Yecies, Nicole E. Carlson, Jing Deng et al. · Blood · 2010 · 355 citations · Full text
Medicine, Cell Biology, Oncology +14
History of the Development of Arsenic Derivatives in Cancer Therapy
Samuel Waxman, Kenneth C. Anderson · The Oncologist · 2001 · 354 citations · Full text
Medicine, Oncology, Toxicology +13